Projects funded by the NCN

MOLECULES BINDING DNA - SYNTHESIS AND PROPERTIES OF DNA INTERCALATORS CONTAINING BORON CLUSTERS.

Call: SONATA BIS 4 , Panel: ST5

Principal investigator: dr hab. Agnieszka Bogusława Olejniczak

Instytut Biologii Medycznej Polskiej Akademii Nauk

Improving the therapeutic potential of cytostatics through the use of abiotic metallacarboranes.

Call: PRELUDIUM 23 , Panel: NZ7

Principal investigator: Michalina Gos

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Cellular and molecular basis of antifungal activity of metallacarboranes against Candida albicans

Call: OPUS 27 , Panel: NZ7

Principal investigator: dr hab. Konrad Kubiński

Katolicki Uniwersytet Lubelski Jana Pawła II

Metallacarborane-peptide amphiphiles as a new strategy in the fight against multidrug-resistant Gram-negative bacteria

Call: SONATA 19 , Panel: NZ7

Principal investigator: dr Krzysztof Konrad Fink

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

unESKAPEable. Innovative antibiotics leads based on bifunctionalsed metallacarboranes to combat ESKAPE pathogens.

Call: PRELUDIUM 22 , Panel: NZ7

Principal investigator: Jakub Cebula

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Make an old drug great again – isoniazid/rifamycin-boron clusters conjugates – synthesis and antitubercular activity....

Call: OPUS 20 , Panel: NZ7

Principal investigator: dr hab. Agnieszka Bogusława Olejniczak

Instytut Biologii Medycznej Polskiej Akademii Nauk

Insulin – metallacarborane conjugates: A new strategy to enhance the biological efficacy of peptide drugs

Call: PRELUDIUM BIS 1 , Panel: NZ7

Principal investigator: dr hab. Tomasz Marek Goszczyński

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Conjugates of metallacarboranes and short cationic peptides with antibacterial and anticancer activity.

Call: SONATINA 3 , Panel: NZ7

Principal investigator: dr Krzysztof Konrad Fink

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk